Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SNCA | P37840 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 4/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL510812 | 0.92 | HIF1A (0.43) | HIF1ACYP2C19CYP1A2CYP2D6ALDH1A1 | |
| Iodide SCHEMBL5158487 | 0.89 | HIF1A (0.43) | HIF1ACYP2C19CYP1A2CYP2D6ALDH1A1 | |
| Bromide SCHEMBL667642 | 0.82 | HIF1A (0.47) | HIF1ACYP2C19CYP1A2CYP2D6ALDH1A1 | |
| Hydrochloric Acid SCHEMBL8583704 | 0.79 | HIF1A (0.47) | HIF1ACYP2C19CYP1A2CYP2D6ALDH1A1 | |
| Bromide SCHEMBL1454426 | 0.74 | HIF1A (0.50) | HIF1ACYP2C19CYP1A2CYP2D6ALDH1A1 | |
| Bromide SCHEMBL11597153 | 0.73 | CYP2C19 (0.41) | HIF1ACYP2C19 | |
| Bromide SCHEMBL7858777 | 0.72 | TDP1 (0.35) | HIF1ATDP1 | |
| Bromide SCHEMBL6428595 | 0.71 | HIF1A (0.44) | HIF1ACYP2C19CYP1A2CYP2D6ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28584063 | 0.71 | HIF1A (0.44) | HIF1ACYP2C19CYP1A2CYP2D6ALDH1A1 | |
| Water SCHEMBL8528246 | 0.70 | HIF1A (0.50) | HIF1ACYP2C19CYP1A2CYP2D6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0087136-B1 | NOVEL POLYPRENYL COMPOUNDS, METHOD OF PRODUCING THE SAME AND THEIR USE IN DOLICHOL PRODUCTION | KURARAY CO., LTD. (JP) | 1985-07-31 | — | — | EP | claimed |
| EP-0087136-A2 | Novel polyprenyl compounds, method of producing the same and their use in dolichol production | KURARAY CO., LTD. (JP) | 1983-08-31 | — | — | EP | claimed |
| WO-2026087965-A1 | COMPOSITION COMPRISING EPOXY RESIN WITH CONSTRAINED AROMATIC RINGS AND PHOTOBASE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2025200154-A1 | TWO-PART EPOXY COMPOSITION COMPRISING THIOL CURATIVE, AND CATALYST | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2025-10-02 | — | — | WO | disclosed |
| EP-3653663-B1 | MOLDED ARTICLE AND ITS PRODUCTION METHOD | TORAY INDUSTRIES (JP) | 2022-12-28 | — | — | EP | disclosed |
| WO-2022210246-A1 | EPOXY RESIN COMPOSITION, CURED EPOXY RESIN PRODUCT, AND COATED FIBER-REINFORCED RESIN MOLDED ARTICLE OBTAINED USING SAME | 東レ株式会社 | 2022-10-06 | — | — | WO | disclosed |
| CN-113801179-A | Beta-galactosidase fluorescent probe, preparation method and application thereof | 华东理工大学 | 2021-12-17 | — | — | CN | disclosed |
| EP-3653663-A1 | MOLDED ARTICLE AND PRODUCTION METHOD THEREFOR | Toray Industries, Inc. (JP) | 2020-05-20 | — | — | EP | disclosed |
| US-20200148847-A1 | MOLDED ARTICLE AND PRODUCTION METHOD THEREFOR | TORAY INDUSTRIES, INC. (JP) | 2020-05-14 | — | — | US | disclosed |
| EP-1674550-B1 | Liquid crystal compound having chroman ring, liquid crystal composition comprising the compound and liquid crystal display device comprising the composition | CHISSO CORP (JP) | 2008-07-02 | — | — | EP | disclosed |
| US-7247355-B2 | Liquid crystal compound having chroman ring, liquid crystal composition comprising the compound and liquid crystal display device comprising the composition | CHISSO CORPORATION (JP) | 2007-07-24 | — | — | US | disclosed |
| EP-1674550-A1 | Liquid crystal compound having chroman ring, liquid crystal composition comprising the compound and liquid crystal display device comprising the composition | CHISSO CORPORATION (JP) | 2006-06-28 | — | — | EP | disclosed |
| US-20060131540-A1 | Liquid crystal compound having chroman ring, liquid crystal composition comprising the compound and liquid crystal display device comprising the composition | JIANGSU HECHENG DISPLAY TECHNOLOGY CO., LTD. (CN) | 2006-06-22 | — | — | US | disclosed |
| EP-0378850-B1 | Substituted pyrido(2,3-d) pyrimidines | BAYER AG (DE) | 1994-04-06 | — | — | EP | disclosed |
| US-5145959-A | Enzyme inhibitors; antilipemic agents; treatment of atherosclerosis | BAYER AKTIENGESELLSCHAFT (DE) | 1992-09-08 | — | — | US | disclosed |
| US-5110825-A | Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A; anticholesterol, antilipemic, antiatherosclerotic | SHIONOGI & CO., LTD. (JP) | 1992-05-05 | — | — | US | disclosed |
| US-5075311-A | Anticholesterol agents | BAYER AKTIENGESELLSCHAFT (DE) | 1991-12-24 | — | — | US | disclosed |
| US-4564477-A | DOLICHOL INTERMEDIATE | KURARAY CO., LTD. (JP) | 1986-01-14 | — | — | US | disclosed |
| EP-0087136-B1 | NOVEL POLYPRENYL COMPOUNDS, METHOD OF PRODUCING THE SAME AND THEIR USE IN DOLICHOL PRODUCTION | KURARAY CO., LTD. (JP) | 1985-07-31 | — | — | EP | disclosed |
| EP-0087136-A2 | Novel polyprenyl compounds, method of producing the same and their use in dolichol production | KURARAY CO., LTD. (JP) | 1983-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060131540-A1 | Liquid crystal compound having chroman ring, liquid crystal composition comprising the compound and liquid crystal display device comprising the composition | CFH, RCC1, RCC2 | HIF1A 4100/4885CYP2C19 3092/4885CYP1A2 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.